The third in our Myeloma Crowd Radio series for the new Myeloma Crowd Research Initiative (MCRI), we talk with Dr. Robert Orlowski, MD, PhD at MD Anderson Cancer Center about work being done specifically for the highest risk multiple myeloma patients with del17p.  This is a genetic feature with historically poor outcomes. Learn more about the hypothesis that the biology of del17p could be influenced to introducing genes normally repressed by p53 that would create molecular vulnerabilities and result in new targets to improve outcomes.  Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.